Protocol for the MPTP mouse model of Parkinson's disease.
This protocol describes our method of producing a reliable mouse model of Parkinson's disease (PD) using the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We discuss the particulars of the model, provide key references and outline what investigators need to know to develop the MPTP mouse model of PD safely and successfully. Completion of this protocol depends on the regimen of MPTP used and on the actual planned studies, which often range from 7 to 30 d. This protocol calls for implementation of safety measures and for the acquisition of several pieces of equipment, which are a one-time investment worth making if one elects to use this model on a regular basis.
Jackson-Lewis
Vernice
V
Department of Neurology, Columbia University, New York, NY 10032, USA.
Przedborski
Serge
S
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000378:metabolism*; D015102:3,4-Dihydroxyphenylacetic Acid; D000818:Animals; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D051379:Mice; D020734:Parkinsonian Disorders / Q000139:chemically induced*; D013378:Substantia Nigra / Q000166:cytology; D014446:Tyrosine 3-Monooxygenase
D015102:3,4-Dihydroxyphenylacetic Acid; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine